The month ahead: April’s upcoming events
Replimune gets a second chance, while Sarclisa could go subcutaneous.
Akeso casts doubts on CD73 efforts
The company has ditched a trial of drebuxelimab plus ivonescimab.
Sanofi steps back from radioconjugates
The company quietly deprioritises AlphaMedix.
ESMO 2025 – Sanofi takes aim at Lutathera
But Perspective sinks again.
ESMO 2025 preview – Sanofi’s lead shot gets a boost
The group toplines a phase 2 win with Alphamedix.
M&A analysis: signs of life emerge
Some big deals in the second quarter have raised hopes that takeouts are back.
